Activated Charcoal Arsenic Triiodide Causticum Cup

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Compound: Repurposing Evaluation Not Possible

One-Sentence Summary

This entry contains a nine-ingredient combination — including Activated Charcoal, Arsenic Triiodide, Causticum, Cupric Acetate, Drimia Maritima Bulb, Drosera Rotundifolia, Lachesis Muta Venom, Potassium Carbonate, and Protortonia Cacti — consistent with a homeopathic/alternative medicine formulation. The TxGNN model did not generate any predicted indications for this compound, most likely because no DrugBank ID could be matched and the multi-ingredient structure cannot be mapped to the knowledge graph as a single entity. As a result, no evidence of any level is available to support a repurposing direction.

Quick Overview

Item	Content
Original Indication	Not available (no approved indications on record)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	Below L5 (no prediction, no studies)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No prediction was generated, so a mechanistic justification cannot be written.

For context, the nine listed ingredients are consistent with classical homeopathic repertory formulations:

Drosera rotundifolia is frequently cited in homeopathic materia medica for spasmodic cough and pertussis-like symptoms.
Drimia maritima (sea squill) has a long ethnopharmacological history as a cardiac glycoside source and expectorant.
Lachesis muta venom and Potassium Carbonate (Kali Carb) are classical homeopathic polychrests used across a wide range of constitutional and respiratory presentations.
Arsenic Triiodide and Causticum are diluted homeopathic preparations; their pharmacological activity at homeopathic dilutions is not established in the conventional sense.

Because DrugBank does not maintain records for multi-ingredient homeopathic mixtures at this level of specificity, the TxGNN knowledge graph has no node to anchor a prediction. No mechanism of action data is available.

Safety Considerations

Please refer to the package insert for safety information.

Note on Arsenic Triiodide: Even at low concentrations, inorganic arsenic compounds carry regulatory toxicity concerns. If this product is reformulated or investigated at pharmacologically active doses, a dedicated toxicological review will be required before any clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: This compound is a multi-ingredient homeopathic mixture with no DrugBank ID, no approved indication, no US market presence, and no TxGNN prediction. The evidence framework required for a repurposing evaluation does not exist for this entry.

To proceed, the following is needed:

Establish drug identity: Determine whether this combination is sold as a finished product with a known brand name, lot number, or pharmacopoeia reference (e.g., HPUS, HAB, or Ph.Eur. homeopathic monographs).
Assign a lead ingredient: If the intent is to evaluate a single active component (e.g., Drimia maritima glycosides, or arsenic trioxide at oncological doses), the evaluation must be rerun as a single-INN query with a valid DrugBank ID.
Clarify regulatory scope: Homeopathic combinations are exempt from standard NDA pathways in most jurisdictions; confirm whether conventional drug repurposing methodology is the appropriate framework for this product.
Obtain MOA data: If any single ingredient in this mixture has a documented pharmacological mechanism, retrieve it via DrugBank API before resubmitting.
Safety assessment: Retrieve package insert or TFDA product dossier to complete the baseline safety profile, particularly regarding the arsenic and venom components.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.